Fund shareholders of MARKER THERAPEUTICS INC
ISIN US57055L2060 · United States · LEI 549300ZJ2JUDG0FI5Y49
- Fund shareholders
- 6
- Of which ETFs
- 0 6 other funds
- Value held
- 670K $
- Share of capital
- 3.0 % of 16.7M shares on Aug 7, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 261,243 | 339.6K $ | 1.57 % | as of Mar 31, 2026 ↗ | |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 128,076 | 166.5K $ | 0.00 % | 0.77 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 77,121 | 114.1K $ | 0.00 % | 0.46 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 15,555 | 23K $ | 0.09 % | as of Feb 28, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 12,811 | 19K $ | 0.08 % | as of Feb 28, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 5,272 | 7.8K $ | 0.03 % | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 6 | 0 | 500,078 | +43.7 % |
| 2026Q1 | 6 | 0 | 348,088 | -0.1 % |
| 2025Q4 | 6 | 0 | 348,561 | -1.1 % |
| 2025Q3 | 6 | -4 | 352,548 | -4.7 % |
| 2025Q2 | 10 | 0 | 370,062 | +9.1 % |
| 2025Q1 | 10 | -1 | 339,200 | +0.2 % |
| 2024Q4 | 11 | +2 | 338,654 | +6.9 % |
| 2024Q3 | 9 | 0 | 316,930 | +1.5 % |
| 2024Q2 | 9 | 0 | 312,285 | +5.1 % |
| 2024Q1 | 9 | -1 | 297,270 | +0.3 % |
| 2023Q4 | 10 | 296,342 |
Institutional managers
33 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| NEA Management Company, LLC | 1,625,678 | 2.1M $ | as of Mar 31, 2026 |
| Blue Owl Capital Holdings LP | 554,250 | 720.5K $ | as of Mar 31, 2026 |
| Aisling Capital Management LP | 325,370 | 423K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 175,294 | 227.9K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 160,910 | 209.2K $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 93,121 | 121.1K $ | as of Mar 31, 2026 |
| LPL Financial LLC | 83,047 | 108K $ | as of Mar 31, 2026 |
| XTX Topco Ltd | 63,567 | 82.6K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 61,001 | 79.3K $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 48,780 | 63.4K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 36,303 | 47.2K $ | as of Mar 31, 2026 |
| UBS Group AG | 32,369 | 42.1K $ | as of Mar 31, 2026 |
| Invst, LLC | 29,000 | 37.7K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 26,009 | 33.8K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 20,948 | 27.2K $ | as of Mar 31, 2026 |
| Creative Planning | 17,312 | 22.5K $ | as of Mar 31, 2026 |
| Ashton Thomas Private Wealth, LLC | 16,400 | 21.3K $ | as of Mar 31, 2026 |
| MATRIX ASSET ADVISORS INC/NY | 15,000 | 19.5K $ | as of Mar 31, 2026 |
| HRT FINANCIAL LP | 11,852 | 15 $ | as of Mar 31, 2026 |
| TWO SIGMA SECURITIES, LLC | 11,460 | 14.9K $ | as of Mar 31, 2026 |
| FIFTH THIRD BANCORP | 10,000 | 13K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 3,137 | 4.1K $ | as of Mar 31, 2026 |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 2,000 | 2.6K $ | as of Mar 31, 2026 |
| Western Wealth Management, LLC | 368 | 478 $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 232 | 302 $ | as of Mar 31, 2026 |
Cite this page
Titelia. "Fund shareholders of MARKER THERAPEUTICS INC". https://titelia.com/en/stocks/marker-therapeutics-inc-US57055L2060